Please Note: This trial is no longer enrolling new participants
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
| Protocol No. | S1418/BR006 | Scope | National |
|---|---|---|---|
| Principal Investigator | Tarah Ballinger | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
